326 related articles for article (PubMed ID: 28297142)
1. Vismodegib Therapy for Basal Cell Carcinoma in an 8-Year-Old Chinese Boy with Xeroderma Pigmentosum.
Fife D; Laitinen MA; Myers DJ; Landsteiner PB
Pediatr Dermatol; 2017 Mar; 34(2):163-165. PubMed ID: 28297142
[TBL] [Abstract][Full Text] [Related]
2. Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum.
Soura E; Plaka M; Dessinioti C; Chasapi V; Stefanaki C; Antoniou C; Stratigos A
Pediatr Dermatol; 2018 Nov; 35(6):e334-e336. PubMed ID: 30178564
[TBL] [Abstract][Full Text] [Related]
3. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).
Kwon GP; Ally MS; Bailey-Healy I; Oro AE; Kim J; Chang AL; Aasi S; Tang JY
J Am Acad Dermatol; 2016 Jul; 75(1):213-5. PubMed ID: 27317518
[No Abstract] [Full Text] [Related]
4. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
[TBL] [Abstract][Full Text] [Related]
5. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib.
Saintes C; Saint-Jean M; Brocard A; Peuvrel L; Renaut JJ; Khammari A; Quéreux G; Dréno B
J Eur Acad Dermatol Venereol; 2015 May; 29(5):1006-9. PubMed ID: 24980899
[TBL] [Abstract][Full Text] [Related]
6. Regression of a basal cell carcinoma infiltrating the brain after vismodegib therapy.
Kaehler KC; Gutzmer R; Egberts F; Hauschild A
J Dtsch Dermatol Ges; 2014 Oct; 12(10):906-7. PubMed ID: 25041591
[No Abstract] [Full Text] [Related]
7. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
8. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
9. Histologic Findings of Tumor Lysis in Advanced Basal Cell Carcinoma Treated With Vismodegib.
Powell EM; Stratton JS; Shendrik I; Blalock TW
Dermatol Surg; 2016 Jul; 42(7):904-7. PubMed ID: 27191782
[No Abstract] [Full Text] [Related]
10. Vismodegib for periocular and orbital basal cell carcinoma.
Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
[TBL] [Abstract][Full Text] [Related]
11. Vismodegib for Locally Advanced Basal Cell Carcinoma: Descriptive Analysis of a Case Series and Comparison to the Literature.
Viscusi KS; Hanke CW
J Drugs Dermatol; 2015 Sep; 14(9):956-62. PubMed ID: 26355613
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
13. Development of Basal Cell Carcinoma With Squamous Differentiation During Vismodegib Treatment.
Feigenbaum L; Scott BL; Moye MS; Nijhawan RI
Dermatol Surg; 2017 Jul; 43(7):989-991. PubMed ID: 28002101
[No Abstract] [Full Text] [Related]
14. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
15. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
Meani RE; Lim SW; Chang AL; Kelly JW
Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
[TBL] [Abstract][Full Text] [Related]
16. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
17. A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib.
Lucero OM; Fitzmaurice S; Thompson C; Leitenberge J
Dermatol Online J; 2018 Feb; 24(2):. PubMed ID: 29630158
[TBL] [Abstract][Full Text] [Related]
18. Inoperable infiltrative basal cell carcinoma successfully treated with vismodegib.
Zargari O; Azimi SZ; Geranmayeh S
Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28631369
[TBL] [Abstract][Full Text] [Related]
19. Vismodegib for locally advanced basal cell carcinoma in a heart transplant patient.
Cusack CA; Nijhawan R; Miller B; Henien M; Malat G; Doyle A; Abdelmalek M
JAMA Dermatol; 2015 Jan; 151(1):70-2. PubMed ID: 25337679
[TBL] [Abstract][Full Text] [Related]
20. [Vismodegib Therapy for Periocular Basal Cell Carcinoma].
Keserü M; Green S; Dulz S
Klin Monbl Augenheilkd; 2017 Jan; 234(1):64-69. PubMed ID: 28135752
[No Abstract] [Full Text] [Related]
[Next] [New Search]
